可溶性Endoglin在前列腺癌诊断中的临床意义

Soluble Endoglin clinical significance in the diagnosis of prostate cancer

目的:研究可溶性Endoglin在前列腺癌患者血清中的表达水平,结合临床中PSA水平和术后病理结果探讨可溶性Endoglin在前列腺癌诊断中的应用。方法:在临床中分别收集20例前列腺癌患者、20例前列腺增生以及15例健康患者血浆,均取离心后的血清,用ELISA法分别测定每个血清标本中的Endoglin浓度,用电化学免疫法测定每个标本的PSA进行对比,用软件统计包进行统计分析。结果:可溶性Endoglin分别在前列癌、前列腺增生患者和健康人血液中表达水平为(6.23±1.12)μg/L、(2.70±1.89)μg/L、(2.37±1.13)μg/L,前列腺癌组高于前列腺增生和健康对照组(P<0.05),在前列腺癌诊断中Endoglin的阳性率为75%。结论:通过检测Endoglin在血液中的表达对前列腺癌的早期诊断具有一定的辅助作用,在临床中可以作为一项检测指标联合其他因子检测加强特异性。

Objective： the purpose of this paper is to study soluble Endoglin in the expression level of prostate cancer patients serum, combined with clinical PSA and postoperative pathological results discussed in soluble Endoglin in the diagnosis of prostate cancer. Methods： 20 cases of prostate cancer were collected respectively in clinical, 20 patients with hyperplasia of prostate and 15 cases of healthy blood plasma, all take the serum after the centrifugal, were determined by ELISA method each concentration of serum specimen Endoglin, electricity chemical immune method, comparing the determination of each specimen PSA with statistical software package for statistical analysis. Results： soluble Endoglin in prostate cancer, prostatic hyperplasia patients and healthy people expression levels in the blood for （6.23±1.12） （2.70 ± 1.89） （2.37 ± 1.13） units： mu g/L, the prostate cancer group is higher than the hyperplasia of prostate and healthy controls （P〈0.05） in the diagnosis of prostate cancer Endoglin positive rate was 75%. Conclusion： by detecting Endogtin in the blood for the early diagnosis of prostate cancer has certain auxiliary function, can be used as a testing index in clinical joint other factor to strengthen specificity of detection.